Zobrazeno 1 - 10
of 37
pro vyhledávání: '"E I, BORISOVA"'
Autor:
E. I. Borisova, S. L. Gutorov
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 42-47 (2021)
Tyrosine kinase inhibitors of the first, second and third generations are the main treatment method for non-small cell lung cancer with EGFR mutation. About 60% of patients progressing on a first-generation or second-generation tyrosine kinase inhibi
Externí odkaz:
https://doaj.org/article/939476aa46b44181ae795b9be18bd515
Publikováno v:
Экономика: стратегия и практика, Vol 16, Iss 2, Pp 178-187 (2021)
The difficulty of conducting an empirical assessment of the true extent of corruption, caused by the lack of the necessary data, has contributed to the emergence of a new round of research focusing on the study of the influence of various factors on
Externí odkaz:
https://doaj.org/article/c28b387e914b40f6ac36f39c2f9e6fcd
Autor:
O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, A. A. Meshcheryakov
Publikováno v:
Опухоли женской репродуктивной системы, Vol 16, Iss 2, Pp 25-37 (2020)
Background. Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods.
Externí odkaz:
https://doaj.org/article/b567c6b98dcc4c59b312427d125b37b7
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 38-43 (2019)
Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase domain, which has shown effectiveness in the treatment of non-small cell lung cancer with activating EGFR mutation. A number of large randomized studies have shown a significant increase
Externí odkaz:
https://doaj.org/article/c23f9738d9c44bb8b2ab6b4c12f1052c
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 56-60 (2018)
The article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable toxicity in comparison with traditional taxanes. The low frequency of hypersensitivity reactio
Externí odkaz:
https://doaj.org/article/828fe9378db24020b033974b516a9be6
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 42-49 (2018)
A study that enrolled 30 patients with advanced colorectal cancer, who had not previously received any specific drug treatment, was conducted to develop and study a three-component regimen with oral fluoropyrimidine tegafur (Ftorafur) in outpatient p
Externí odkaz:
https://doaj.org/article/8c8f06961c0947918a488b8c520ae5a4
Autor:
O. E. Kondratieva, M. E. Abramov, G. V. Vyshinskaya, S. L. Gutorov, E. I. Borisova, E. V. Cherniglazova
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 134-139 (2018)
Anemia is a common hematological complication in cancer patients receiving chemotherapy. Reduction of hemoglobin level is accompanied by a significant deterioration in the patients’ life quality. A transfusion of erythrocyte mass is used to rapidly
Externí odkaz:
https://doaj.org/article/d16d7184b8784ff5b0ed46ab1e009f7c
Autor:
E. I. Borisova, S. L. Gutorov
Publikováno v:
Медицинский совет, Vol 0, Iss 8, Pp 60-65 (2015)
Introduction of toremifene into clinical practice significantly enhances the potential of current endocrine therapy for luminal subtypes of breast cancer. Toremifene demonstrates same or greater efficacy compare with tamoxifen but has a more favorabl
Externí odkaz:
https://doaj.org/article/dd3c8cbb7da249389c909afaecf5abc5
Publikováno v:
Medical alphabet. 1:20-24
In most cases triple negative breast cancer is characterized by an aggressive course of disease and early development of resistance to chemotherapy. Thereafter, the late-line treatment choice, usually after anthracyclines and taxanes, is problematic
Autor:
E. I. Borisova
Publikováno v:
Библиосфера, Vol 0, Iss 4, Pp 41-44 (2014)
A debatable issue at the present stage of libraries development is finding a compromise between the public interest in a public library services for Russian citizens and the private interests of rights holders to ensure their intellectual property ri
Externí odkaz:
https://doaj.org/article/1e794ff4835b4c7ca31fb5fd8f71c60f